Nanobiotix (NANOB)

Currency in EUR
31.08
+1.12(+3.74%)
Closed·
Advertisement
NANOB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
29.1231.18
52 wk Range
3.9547.66
Key Statistics
Prev. Close
29.96
Open
29.66
Day's Range
29.12-31.18
52 wk Range
3.95-47.66
Volume
93.53K
Average Volume (3m)
230.44K
1-Year Change
667.4074%
Book Value / Share
-1.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NANOB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.80
Upside
+53.80%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has fared poorly over the last month

Nanobiotix News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 47.80
(+53.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy45.00+44.79%23.00Maintain13/03/2026
Stifel
Buy25.00-19.56%17.00Maintain08/10/2025
Jefferies
Buy21.00-32.43%8.00Maintain06/10/2025

Earnings

Latest Release
29/05/2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare NANOB to Peers and Sector

Metrics to compare
NANOB
Peers
Sector
Relationship
P/E Ratio
−63.4x−2.0x−0.4x
PEG Ratio
−1.01−0.020.00
Price/Book
−18.0x0.4x2.6x
Price / LTM Sales
46.6x16.2x3.0x
Upside (Analyst Target)
44.8%259.6%56.2%
Fair Value Upside
Unlock8.4%8.9%Unlock

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

Employees
100
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.66M5.49%80.34M
Other Institutional Investors
26.01M53.59%784.89M
Public Companies & Retail Investors
19.86M40.92%599.38M
Total
48.53M100.00%1.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Artal Group S.A.12.04%5,844,592176,390
Invus Public Equities, L.P.12.04%5,844,592176,390

People Also Watch

27.46
ELIS
+0.37%
13.60
OVH
+1.49%
0.2345
ALSEN
0.00%
9.72
DBG
-2.41%
4.585
ALMDT
+4.68%

FAQ

What Is the Nanobiotix (Paris: NANOB) Share Price Today?

The Nanobiotix stock price today is 31.08 EUR.

What Stock Exchange Does Nanobiotix (NANOB) Trade On?

Nanobiotix is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Nanobiotix?

The stock symbol (also called a 'ticker') for Nanobiotix is "NANOB."

What Is the Current Nanobiotix Market Capitalisation?

As of today, Nanobiotix (Paris: NANOB) market cap is 1.58B EUR.

What Is Nanobiotix's (NANOB) Earnings Per Share (TTM)?

The Nanobiotix EPS is currently -0.50 (Trailing Twelve Months).

When Is the Next Nanobiotix Earnings Date?

Nanobiotix's next earnings report will be released on 30/09/2026.

Is NANOB a Buy or Sell From a Technical Analyst Perspective?

Based on today's Nanobiotix moving averages and other technical indicators, the daily buy/sell signal for NANOB stock is Buy.

How Many Times Has Nanobiotix Stock Split?

Nanobiotix has split 1 times. (See the NANOB stock split history page for full effective split date and price information.)

How Many Employees Does Nanobiotix Have?

Nanobiotix has 100 employees, based on their latest Companies House report.

What is the current trading status of Nanobiotix (Paris: NANOB)?

As of 27/06/2026, Nanobiotix (NANOB) is trading at a share price of 31.08 EUR, with a previous close of 29.96 EUR. The stock has fluctuated within a day range of 29.12 EUR to 31.18 EUR, while its 52-week range spans from 3.95 EUR to 47.66 EUR.

What Is Nanobiotix (NANOB) Price Target According to Analysts?

The average 12-month price target for Nanobiotix is 47.80 EUR, with a high estimate of 60 EUR and a low estimate of 34 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +53.80% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.